Vivos Therapeutics (NASDAQ:VVOS) Trading 9.9% Higher – Time to Buy?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was up 9.9% during mid-day trading on Tuesday . The company traded as high as $0.54 and last traded at $0.4622. 33,641,816 shares were traded during mid-day trading, an increase of 22,065% from the average daily volume of 151,780 shares. The stock had previously closed at $0.4206.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on VVOS. Ascendiant Capital Markets increased their target price on shares of Vivos Therapeutics from $3.00 to $3.10 and gave the company a “buy” rating in a research note on Thursday, June 4th. HC Wainwright cut their price objective on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Vivos Therapeutics currently has an average rating of “Hold” and an average target price of $2.80.

Vivos Therapeutics Trading Up 9.9%

The company’s 50-day moving average is $0.51 and its two-hundred day moving average is $1.00. The firm has a market cap of $6.42 million, a P/E ratio of -0.22 and a beta of 6.22.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.07). The company had revenue of $5.14 million for the quarter, compared to the consensus estimate of $4.35 million. Vivos Therapeutics had a negative net margin of 127.70% and a negative return on equity of 2,325.64%. Research analysts anticipate that Vivos Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VVOS. Connective Capital Management LLC purchased a new stake in shares of Vivos Therapeutics during the third quarter worth about $620,000. DRW Securities LLC lifted its position in Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares during the period. B. Riley Wealth Advisors Inc. purchased a new stake in Vivos Therapeutics in the second quarter valued at $220,000. Sequoia Financial Advisors LLC acquired a new stake in Vivos Therapeutics during the 1st quarter worth about $28,000. Finally, XTX Topco Ltd acquired a new stake in Vivos Therapeutics during the 2nd quarter worth about $65,000. 26.35% of the stock is currently owned by institutional investors.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.